Oral Session 2-9C Multiple Myeloma: Basic (Novel Molecular Targets）

[OS2-9C-6] Preclinical activities of a novel BMI1 inhibitor PTC596 in multiple myeloma

Yurie Nagai¹, Naoya Mimura^1,2, Ola Rizq³, Yusuke Isshiki¹, Motohiko Oshima⁴, Atsunori Saraya⁵, Mohamed Rizk⁴, Yaeko Nakajima⁴, Nagisa Oshima¹, Shokichi Tsukamoto¹, Shio Mitsukawa^1,2, Yusuke Takeda¹, Masahiro Takeuchi¹, Chikako Ohwada¹, Tohru Iseki^1,2, Chiaki Nakaseko^1,6, Atsushi Iwama⁴, Emiko Sakaida¹ (1.Department of Hematology, Chiba University Hospital, 2.Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3.Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA, 4.Stem Cell and Molecular Medicine, IMS, The University of Tokyo, 5.Department of Cellular and Molecular Medicine, Chiba University Graduate School, 6.Department of Hematology, International University of Health and Welfare School)